Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Feb;91(2):250-6.
doi: 10.1136/hrt.2004.042473.

Left ventricular hypertrophy in hypertension: its arrhythmogenic potential

Thomas Kahan  1 , Lennart Bergfeldt
Affiliations
Review

Left ventricular hypertrophy in hypertension: its arrhythmogenic potential

Thomas Kahan et al. Heart. 2005 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Left ventricular hypertrophy, a condition with variable background. AMI, acute myocardial infarction; CMP, cardiomyopathy.
Figure 2
Figure 2
Common and often co-existing cardiovascular conditions with a risk for adverse events including sudden death.
Figure 3
Figure 3
Left ventricular hypertrophy from an electromechanical perspective.
Figure 4
Figure 4
The risk for cardiac events in hypertension. LV, left ventricular. Adapted from Kahan.
Figure 5
Figure 5
Multiple determinants for left ventricular hypertrophy. Adapted from Kahan.
Figure 6
Figure 6
Left ventricular (LV) geometry in hypertension: four patterns with different prognostic implications.
Figure 7
Figure 7
Some angiotensin II related effects of relevance for arrhythmogenesis. See text for details and references. NA, noradrenaline/norepinephrine.
See this image and copyright information in PMC

References

    1. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001;141:334–41. ▸ A recent meta-analysis of the prognostic implications of LV mass. - PubMed
    1. Lips DJ, deWindt LJ, van Kraaij DJW, et al. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 2003;24:883–96. ▸ A recent review of the molecular background to left ventricular hypertrophy with a haemodynamic focus. - PubMed
    1. Pacifico A, Henry PD. Structural pathways and prevention of heart failure and sudden death. J Cardiovasc Electrophysiol 2003;14:764–75. ▸ Myocardial disease associated with heart failure and sudden cardiac death reviewed from a macroscopic and microscopic anatomy perspective with a focus on the prevention of sudden cardiac death. - PubMed
    1. Kahan T . The importance of left ventricular hypertrophy in human hypertension. J Hypertens 1998;16 (suppl 7) :S23–9. - PubMed
    1. Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003;108:560–5. - PubMed

MeSH terms